<DOC>
	<DOCNO>NCT00003758</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist cytarabine plus idarubicin treating patient relapse acute myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Relapsed Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess feasibility efficacy intermediate dose cytarabine plus idarubicin follow low dose cytarabine patient relapse acute myelogenous leukemia . OUTLINE : This multicenter study . Patients receive intermediate dose cytarabine IV 2 hour twice day day 1-5 , idarubicin IV 24 hour day 1 , 3 , 5 , low dose cytarabine IV 24 hour day 6-15 . If patient achieve complete remission day 35 , regimen repeat . If patient achieve partial remission day 35 , regimen repeat , except additional day idarubicin day 7 . If patient achieve complete remission day 70 , regimen repeat . Patients may undergo stem cell transplantation within 6 month achieve complete remission . Patients HLA identical sibling available receive allogeneic transplant ; others receive autologous transplant . Patients follow monthly 1 year , every 3 month 3 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 24-60 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : First bone marrow relapse primary acute myelogenous leukemia ( AML ) , subtypes except M3 OR First bone marrow relapse secondary AML occur malignancy , cure , alkylating agent and/or radiotherapy , myelodysplastic syndrome No previously untreated AML second subsequent relapse AML No isolate extramedullar localization AML Must achieve first complete remission No leukemia myeloproliferative disease PATIENT CHARACTERISTICS : Age : 15 60 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN AST great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No cardiac contraindication anthracycline chemotherapy Ventricular ejection fraction least 45 % Other : No uncontrolled infection No concurrent severe neurological psychiatric disease No progressive malignant nonhematological disease PRIOR CONCURRENT THERAPY : Biologic therapy : No prior allogeneic autologous bone marrow peripheral stem cell transplant Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>childhood acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>